210 related articles for article (PubMed ID: 20872084)
21. Optimizing anti-TNF treatment in inflammatory bowel disease.
Rutgeerts P; Van Assche G; Vermeire S
Gastroenterology; 2004 May; 126(6):1593-610. PubMed ID: 15168370
[TBL] [Abstract][Full Text] [Related]
22. Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: effects of combined therapy with immunosuppressants.
Andrisani G; Frasca D; Romero M; Armuzzi A; Felice C; Marzo M; Pugliese D; Papa A; Mocci G; De Vitis I; Rapaccini GL; Blomberg BB; Guidi L
J Crohns Colitis; 2013 May; 7(4):301-7. PubMed ID: 22673636
[TBL] [Abstract][Full Text] [Related]
23. Is there a benefit from the concomitant use of immunosupression with anti-TNF in Crohn's disease; heads or tails?
Lakatos PL
Rev Recent Clin Trials; 2009 Sep; 4(3):152-8. PubMed ID: 20028325
[TBL] [Abstract][Full Text] [Related]
24. Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease.
Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
Clin Gastroenterol Hepatol; 2016 Aug; 14(8):1120-1129.e6. PubMed ID: 27058635
[TBL] [Abstract][Full Text] [Related]
25. Infliximab does not affect postoperative complication rates in Crohn's patients undergoing abdominal surgery.
Kasparek MS; Bruckmeier A; Beigel F; Müller MH; Brand S; Mansmann U; Jauch KW; Ochsenkühn T; Kreis ME
Inflamm Bowel Dis; 2012 Jul; 18(7):1207-13. PubMed ID: 21928373
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of Infliximab in Crohn's Disease Patients with Prior Primary-Nonresponse to Tumor Necrosis Factor Antagonists.
Clark-Snustad KD; Singla A; Lee SD
Dig Dis Sci; 2019 Jul; 64(7):1952-1958. PubMed ID: 30815825
[TBL] [Abstract][Full Text] [Related]
27. The classics in perspective.
Panés J; Ghosh S
Gut; 2007 Sep; 56(9):1184-6. PubMed ID: 17698863
[No Abstract] [Full Text] [Related]
28. Anti-tumor necrosis factor and postoperative complications in Crohn's disease: systematic review and meta-analysis.
Kopylov U; Ben-Horin S; Zmora O; Eliakim R; Katz LH
Inflamm Bowel Dis; 2012 Dec; 18(12):2404-13. PubMed ID: 22467533
[TBL] [Abstract][Full Text] [Related]
29. Anti-TNF biologic therapy does not increase postoperative morbidity in pediatric Crohn's patients.
Lightner AL; McKenna NP; Alsughayer A; Loftus EV; Raffals LE; Faubion WA; Moir C
J Pediatr Surg; 2019 Oct; 54(10):2162-2165. PubMed ID: 30773391
[TBL] [Abstract][Full Text] [Related]
30. Anti-TNF Therapy Is Associated With an Increased Risk of Postoperative Morbidity After Surgery for Ileocolonic Crohn Disease: Results of a Prospective Nationwide Cohort.
Brouquet A; Maggiori L; Zerbib P; Lefevre JH; Denost Q; Germain A; Cotte E; Beyer-Berjot L; Munoz-Bongrand N; Desfourneaux V; Rahili A; Duffas JP; Pautrat K; Denet C; Bridoux V; Meurette G; Faucheron JL; Loriau J; Guillon F; Vicaut E; Benoist S; Panis Y;
Ann Surg; 2018 Feb; 267(2):221-228. PubMed ID: 29300710
[TBL] [Abstract][Full Text] [Related]
31. Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.
Smith LS; Nelson M; Dolder CR
Ann Pharmacother; 2010 Feb; 44(2):333-42. PubMed ID: 20118143
[TBL] [Abstract][Full Text] [Related]
32. Induction or exacerbation of psoriasis in patients with Crohn's disease under treatment with anti-TNF antibodies.
Barthel C; Biedermann L; Frei P; Vavricka SR; Kündig T; Fried M; Rogler G; Scharl M
Digestion; 2014; 89(3):209-15. PubMed ID: 24853251
[TBL] [Abstract][Full Text] [Related]
33. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.
Sandborn WJ; Rutgeerts P; Enns R; Hanauer SB; Colombel JF; Panaccione R; D'Haens G; Li J; Rosenfeld MR; Kent JD; Pollack PF
Ann Intern Med; 2007 Jun; 146(12):829-38. PubMed ID: 17470824
[TBL] [Abstract][Full Text] [Related]
34. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease.
Stidham RW; Lee TC; Higgins PD; Deshpande AR; Sussman DA; Singal AG; Elmunzer BJ; Saini SD; Vijan S; Waljee AK
Aliment Pharmacol Ther; 2014 Jun; 39(12):1349-62. PubMed ID: 24749763
[TBL] [Abstract][Full Text] [Related]
35. Increased hospitalizations in elderly with inflammatory bowel disease on anti-tumor necrosis factor therapy but not increased infections: a community practice experience.
Shen H; Lipka S; Katz S
J Crohns Colitis; 2014 Aug; 8(8):898-9. PubMed ID: 24434182
[No Abstract] [Full Text] [Related]
36. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
37. Meta-analysis: peri-operative anti-TNFα treatment and post-operative complications in patients with inflammatory bowel disease.
Narula N; Charleton D; Marshall JK
Aliment Pharmacol Ther; 2013 Jun; 37(11):1057-64. PubMed ID: 23581515
[TBL] [Abstract][Full Text] [Related]
38. The impact of preoperative serum anti-TNFα therapy levels on early postoperative outcomes in inflammatory bowel disease surgery.
Lau C; Dubinsky M; Melmed G; Vasiliauskas E; Berel D; McGovern D; Ippoliti A; Shih D; Targan S; Fleshner P
Ann Surg; 2015 Mar; 261(3):487-96. PubMed ID: 24950263
[TBL] [Abstract][Full Text] [Related]
39. Correlations between skin lesions induced by anti-tumor necrosis factor-α and selected cytokines in Crohn's disease patients.
Włodarczyk M; Sobolewska A; Wójcik B; Loga K; Fichna J; Wiśniewska-Jarosińska M
World J Gastroenterol; 2014 Jun; 20(22):7019-26. PubMed ID: 24944497
[TBL] [Abstract][Full Text] [Related]
40. The risks of post-operative complications following pre-operative infliximab therapy for Crohn's disease in patients undergoing abdominal surgery: a systematic review and meta-analysis.
Rosenfeld G; Qian H; Bressler B
J Crohns Colitis; 2013 Dec; 7(11):868-77. PubMed ID: 23466411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
